Amgen gets Japanese authorization for migraine drug
The Japanese health authorities have given sales and marketing of Amgen's migraine drug Aimovig in the country the green light.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY NIELSINE NIELSEN
The Japanese health authority Pharmaceuticals and Medical Devices Agency (PMDA) has approved the migraine drug Aimovig produced by US biopharmaceutical company Amgen for sales and marketing in Japan, according to an Amgen press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
US dermatology top boss moves to Danish biotech firm
For subscribers
FDA approves migraine pill as preventative treatment
For subscribers
.jpg&w=384&q=75)
